Genesis Today brings Wake Me, Relax Me to Walmart
AUSTIN, Texas — Genesis Today has introduced two functional beverages exclusively at Walmart.
The company said that its Wake Me and Relax Me drinks are designed to help consumers respectively energize and relax in a healthy way.
Wake Me blends together vitamins and nutrients in a tangerine-orange juice and includes 500% daily value of vitamin B12, theanine, guarana seed and green tea leaf extract.
Relax Me, meanwhile, is a berry tea blend that promotes healthy sleep cycles, lower anxiety levels and overall calmness with melatonin, theanine, tryptophan and other natural compounds. It also contains extract from the montmorency cherry, a natural source of melatonin, Genesis Today said.
"Our Wake Me and Relax Me beverages harness the power of nature to halt this cycle by providing the super-nutrients the body needs to naturally boost energy and rest easily," Genesis Today founder, president and CEO Lindsey Duncan said. "Wake Me and Relax Me are easy additions to your daily routine. We’ve combined great taste with serious functionality and made it easy, accessible and affordable for everyone to look and feel better from the inside out."
Urinozinc expands retail distribution to GNC
MIAMI — A dietary supplement that is designed to alleviate the symptoms of an enlarged prostate has arrived at GNC.
Urinozinc prostate formula now is available at all corporate-owned GNC Live Well stores and at select GNC franchise stores, the company said. Product ingredients for Urinozinc include saw palmetto extract, pumpkin seed, zinc, pygeum africanum, lycopene, magnesium, selenium, folic acid and vitamins B6, B12 and E.
Urinozinc currently is available for purchase at such retail locations as Bi-Lo, Duane Reade, H-E-B, Publix, Rite Aid, Walgreens and Walmart.
Report: GSK brands on sales block peak interest
BRUSSELS — GlaxoSmithKline has garnered strong interest in its portfolio of legacy brands that were placed on the sales block earlier this year, according to a Reuters report published Tuesday. And that interest is likely to pick up in the coming months, GSK CEO Andrew Witty told reporters during a meeting of pharmaceutical industry executives.
The interest is coming from both established consumer healthcare companies, as well as private equity houses, the report noted.
Citing industry analysts, Reuters reported the auction is expected to generate between $2.2 billion and $2.9 billion. The products being auctioned accumulated sales of approximately $816.9 million in 2010. The brand names being sold include analgesics Solpadeine, BC and Goody’s; vitamin and supplement product Abtei; feminine hygiene treatment Lactacyd; and Alli for weight management.